Nanomedicines for cardiovascular disease

BR Smith, ER Edelman - Nature Cardiovascular Research, 2023‏ - nature.com
The leading cause of death in the world, cardiovascular disease (CVD), remains a
formidable condition for researchers, clinicians and patients alike. CVD comprises a broad …

[HTML][HTML] Current status of nanoscale drug delivery and the future of nano-vaccine development for leishmaniasis–A review

P Prasanna, P Kumar, S Kumar, VK Rajana… - Biomedicine & …, 2021‏ - Elsevier
The study of tropical diseases like leishmaniasis, a parasitic disease, has not received much
attention even though it is the second-largest infectious disease after malaria. As per the …

Ultraselective carbon nanotubes for photoacoustic imaging of inflamed atherosclerotic plaques

M Gifani, DJ Eddins, H Kosuge, Y Zhang… - Advanced functional …, 2021‏ - Wiley Online Library
Disruption of vulnerable atherosclerotic plaques often leads to myocardial infarction and
stroke, the leading causes of morbidity and mortality in the United States. A diagnostic …

Pro-efferocytic nanotherapies reduce vascular inflammation without inducing anemia in a large animal model of atherosclerosis

S Bamezai, Y Zhang, M Kumari, M Lotfi… - Nature …, 2024‏ - nature.com
Atherosclerosis is an inflammatory disorder responsible for cardiovascular disease.
Reactivation of efferocytosis, the phagocytic removal of cells by macrophages, has emerged …

Nanotechnology in coronary heart disease

J Guo, H Wang, Y Li, S Zhu, H Hu, Z Gu - Acta Biomaterialia, 2023‏ - Elsevier
Coronary heart disease (CHD) is one of the major causes of death and disability worldwide,
especially in low-and middle-income countries and among older populations. Conventional …

Recent Advancement in Nanotechnology based Drug Delivery for the Management of Cardiovascular disease.

A Ullah, M Ullah, SI Lim - Current problems in cardiology, 2024‏ - Elsevier
Cardiovascular diseases (CVDs) constitute a predominant cause of both global mortality
and morbidity. To address the challenges in the early diagnosis and management of CVDs …

Nanoparticles to target and treat macrophages: the Ockham's concept?

M Medrano-Bosch, A Moreno-Lanceta… - Pharmaceutics, 2021‏ - mdpi.com
Nanoparticles are nanomaterials with three external nanoscale dimensions and an average
size ranging from 1 to 1000 nm. Nanoparticles have gained notoriety in technological …

Targeting macrophages using nanoparticles: a potential therapeutic strategy for atherosclerosis

X Zang, M Cheng, X Zhang, X Chen - Journal of Materials Chemistry B, 2021‏ - pubs.rsc.org
Atherosclerosis is one of the leading causes of vascular diseases, with high morbidity and
mortality worldwide. Macrophages play a critical role in the development and local …

The potential of hydrogen sulfide donors in treating cardiovascular diseases

YZ Wang, EE Ngowi, D Wang, HW Qi, MR **g… - International journal of …, 2021‏ - mdpi.com
Hydrogen sulfide (H2S) has long been considered as a toxic gas, but as research
progressed, the idea has been updated and it has now been shown to have potent …

Emerging concepts of vascular cell clonal expansion in atherosclerosis

A Misra, R Rehan, A Lin, S Patel… - … thrombosis, and vascular …, 2022‏ - Am Heart Assoc
Clonal expansion is a process that can drive pathogenesis in human diseases, with
atherosclerosis being a prominent example. Despite advances in understanding the etiology …